Risk Factors for Cyclosporine-Induced Nephropathy in Patients with Autoimmune Diseases

New England Journal of Medicine

Volumn 326, Issue 25, 1992, Pages 1654-1660

  Feutren, Gilles ^a,b   Mihatsch, Michael J ^c  

^a International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases ^*  (United States)

^b Sandoz Pharma Ltd   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN;

ADULT; ARTERIAL PRESSURE; ARTICLE; AUTOIMMUNITY; CLINICAL FEATURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG THERAPY; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; POLYCHONDRITIS; PRIORITY JOURNAL; PSORIASIS; RISK ASSESSMENT; RISK FACTOR; SJOEGREN SYNDROME; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL; UVEITIS;

ADOLESCENT; ADULT; AGE FACTORS; AUTOIMMUNE DISEASES; BLOOD PRESSURE; CREATININE; CYCLOSPORINE; DIABETES MELLITUS, INSULIN-DEPENDENT; FEMALE; HUMAN; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGE; MULTIVARIATE ANALYSIS; PSORIASIS; RETROSPECTIVE STUDIES; RISK FACTORS; SJOGREN'S SYNDROME; SUPPORT, NON-U.S. GOV'T; UVEITIS;

EID: 0026694617     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199206183262502     Document Type: Article

References (26)

1. Mihatsch MJ, Thiel G, Spichtin HP, et al. Morphological findings in kidney transplants after treatment with cyclosporine. Transplant Proc 1983; 15: Suppl 1: 2821–35.
2. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporineassociated chronic nephropathy. N Engl J Med 1984; 311: 699–705.
3. Palestine AG, Austin HA III, Baiow JE, et al. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med 1986; 314: 1293–8.
4. Svenson K, Bohman SO, Hallgren R. Renal interstitial fibrosis and vascular changes: occurrence in patients with autoimmune diseases treated with cyclosporine. Arch Intern Med 1986; 146: 2007–10.
5. Mihatsch MJ, Thiel G, Ryffel B. Morphology of ciclosporin nephropathy. Prog Allergy 1986; 38: 447–65.
6. Mihatsch MJ, Bach JF, Coovadia HM, et al. Cyclosporin-associated nephropathy in patients with autoimmune diseases. Klin Wochenschr 1988; 66: 43–7.
7. Feutren G. Functional consequences and risk factors of chronic cyclosporine nephrotoxicity in type I diabetes trials. Transplant Proc 1988; 20: Suppl 4: 356–66.
8. Bougneres PF, Carel JC, Castano L, et al. Factors associated with early remission of Type I diabetes in children treated with cyclosporine. N Engl J Med 1988; 318: 663–70.
9. The Canadian-European Randomized Control Trial Group. Cyclosporin-induced remission of IDDM after early intervention: association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 1988; 37: 1574–82.
10. Assan R, Feutren G, Sirmai J, et al. Plasma C-peptide levels and clinical remissions in recent-onset type I diabetic patients treated with cyclosporin A and insulin. Diabetes 1990; 39: 768–74.
11. Donatsch P, Abisch E, Hornberger M, Traber R, Trapp M, Voges R. A radioimmunoassay to measure cyclosporin A in plasma and serum samples. J Immunoassay 1981; 2: 19–32.
12. Eknoyan G. Chronic tubulointerstitial nephropathies. In: Schrier RW, Gottschalk CW, eds. Diseases of the kidney. 4th ed. Boston: Little, Brown, 1988:2191–221.
13. International Kidney Biopsy Registry of Cyclosporin A (Sandimmun) in Autoimmune Diseases. Kidney biopsies in control or cyclosporin A-treated psoriatic patients. Br J Dermatol 1990; 122: Suppl 36: 95–100.
14. SAS user's guide: statistics, release 6.03 ed. Cary, N.C.: SAS Institute, 1988.
15. Miescher PA, Favre H, Chatelanat F, Mihatsch MJ. Combined steroidcyclosporin treatment of chronic autoimmune diseases: clinical results and assessment of nephrotoxicity by renal biopsy. Klin Wochenschr 1987; 65: 727–36.
16. Myers BD, Newton L, Boshkos C, et al. Chronic injury of human renal microvessels with low-dose cyclosporine therapy. Transplantation 1988; 46: 694–703.
17. Bertani T, Ferrazzi P, Schieppati A, et al. Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. Kidney Int 1991; 40: 243–50.
18. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med 1988; 318: 1657–66.
19. Tomlanovich S, Golbetz H, Perlroth M, Stinson E, Myers BD. Limitations of creatinine in quantifying the severity of cyclosporine-induced chronic nephropathy. Am J Kidney Dis 1986; 8: 332–7.
20. Gilbert SC, Emmett M, Menter A, Silverman A, Klintmalm G. Cyclosporine therapy for psoriasis: serum creatinine measurements are an unreliable predictor of decreased renal function. J Am Acad Dermatol 1989; 21: 470–4.
21. Feutren G, Mason J. Serum creatinine or glomerular filtration rate for monitoring cyclosporin therapy. Lancet 1991; 338: 1017.
22. Hoyer PF, Offner G, Wonigeit K, Brodehl J, Pichlmayr R. Dosage of Cyclosporin A in children with renal transplants. Clin Nephrol 1984; 22: 68–71.
23. Thomson SC, Tucker BJ, Gabbai F, Blantz RC. Functional effects on glomerular hemodynamics of short-term chronic cyclosporin in male rats. J Clin Invest 1989; 83: 960–9.
24. Moss NG, Powell SL, Falk RJ. Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats. Proc Natl Acad Sci U S A 1985; 82: 8222–6.
25. Antignac C, Gubler MC, Leverger G, Broyer M, Habib R. Delayed renal failure with extensive mesangiolysis following bone marrow transplantation. Kidney Int 1989; 35: 1336–44.
26. Dieterle A, Gratwohl A, Nizze H, et al. Chronic cyclosporine-associated nephrotoxicity in bone marrow transplant patients. Transplantation 1990; 49: 1093–100.